Abstract Objective: To assess the effectiveness and safety of acupoint injection for the treatment of asthma. Methods: Six electronic databases were searched for randomized controlled trials (RCTs) of acupoint injection for asthma. Two authors extracted data and assessed methodological quality independently using the Cochrane Collaboration Risk of Bias tool. Data were evaluated using RevMan v5.2. Results: Eighteen RCTs involving 1913 participants with asthma were identified. Overall methodological quality of the RCTs was classified as unclear risk of bias. Western medicine (12 RCTs) was injected most frequently into acupoints, followed by Chinese herbal medicine (four RCTs), vitamins (one RCT), and Chinese herbal medicine combined with Western medicine (one RCT). Four RCTs used only one acupoint [ST36 (two RCTs), BL13, CV22], whereas the other RCTs selected multiple acupoints (among which BL13 was used most frequently). One RCT reported mortality, no RCT reported quality of life, 15 RCTs reported the symptom improvement rate, one RCT reported asthma control test (ACT) data, one RCT reported the duration of asthma, three RCTs reported the mean time that asthma was controlled (MTAC), and 13 RCTs reported lung-function tests (LFTs). Some RCTs showed acupoint injection may improve the attack time of asthma, MTAC, and LFTs. Five RCTs reported the outcome of adverse events and showed no significant differences between the acupoint injection group and control group. Conclusions: The findings suggest that acupoint injection may be effective for improving ACT data, duration of asthma, MTAC and LFTs. However, the evidence is insufficient owing to the poor methodological quality of the RCTs. * Corresponding author. Tel.: þ86 10 6428 7002; fax: þ86 10 6428 6871.
Introduction
Asthma is a chronic inflammatory airway disorder characterized by hypersensitivity to various stimuli as well as widespread, episodic, airway obstruction. Worldwide, it affects 300 million people of all ages. 1, 2 Typical symptoms are wheezing, coughing, chest tightness, and dyspnea. 3 Left uncontrolled, asthma can limit daily activities of life and even lead to death. 4 Inhaled corticosteroids are the drugs of choice for relieving asthma symptoms, but are not effective in some patients. 5 Moreover, no treatment for asthma has long-term efficacy for inflammation or remodeling of the airways. Hence, no treatment can modify or cure asthma. 6 In traditional Chinese medicine (TCM), asthma falls under the category of xiao (wheezing) syndrome and chuan (panting) syndrome. One of the earliest records of the condition is found in the Han dynasty (circa 200 CE) text, The Yellow Emperor's Inner Classic (Huang Di Nei Jing). It was not until the Yuan dynasty (1300s CE) that the renowned physician Zhu Danxi introduced the concept of xiaochuan (asthma) as an independent disease. 7 The earliest description of infantile asthma is found in the Ming dynasty (1549) text Elaboration of Pediatrics: Asthma (You Ke Fa Hui: Xiao Chuan).
To treat an asthma attack, when symptoms are present, the principle is to dispel pathogens. This is known as "treating the branch" (symptoms). During asymptomatic periods, the principle of treatment is to reinforce the body's energy (qi). This is known as "treating the root."
Acupoint injection therapy involves injecting medicine (Chinese herbal extractions, Western medications, vitamins, normal saline etc.) into certain acupoints or specific sites based on TCM theories of symptom differentiation and treatment. The advantage of the therapy is that both needling stimulation and administration of medicines are accomplished simultaneously. 8 Nowadays, some systematic reviews have demonstrated that acupoint injection therapy could prevent postoperative ileus and manage burning mouth syndrome. 9, 10 Meanwhile, certain randomized controlled trials (RCTs) indicate that acupoint injection with either Western medicine or Chinese herbal medicine can improve symptom of patients with asthma.
We studied all RCTs on acupoint injection for asthma treatment and evaluated their methodological quality to ascertain the therapeutic effectiveness and safety of acupoint injection for asthma.
Materials and methods

Search strategy
We searched four Chinese (China National Knowledge Infrastructure, Chinese Science and Technology Periodical, Wanfang, SinoMed) and two English databases (PubMed, Cochrane Library). English search terms were "acupoint injection", "acupuncture point injection", and "asthma". Chinese search terms used alone or in combination were "xuewei zhushe (acupoint injection)", "shuizhen (fluid needle injection)", "xiaochuan (asthma)", "xiaozheng (asthma syndrome)", "qichuan (layterm for asthma)". The retrieval mode was adjusted to different databases so that it could be based on MeSH terms or keywords/abstracts to ensure comprehensiveness. These electronic databases were searched from their inception until December 15, 2013 . No language restriction was applied.
Inclusion criteria
We included RCTs on acupoint injection for treatment of participants diagnosed with asthma. We did not limit the type of medications injected: they could be Western drugs or Chinese herbal medicines, or a combination of Western drugs and Chinese herbal medicines. Control interventions could be no treatment, placebo or Western therapy. Cointervention(s) was allowed as long as they were applied in both groups. Primary outcomes were mortality, quality of life (QoL), symptom improvement rate, asthma control test (ACT), duration of asthma mean time that asthma was controlled (MTAC). Secondary outcomes were lung-function tests [LFTs, peak expiratory flow (PEF), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), vital capacity (VC)], cost-effectiveness, and adverse events.
Study selection
Study selection involved seven steps: (1) importing studies obtained from different databases into referencemanagement software (NoteExpress v2.8.1); (2) using NoteExpress to remove duplications; (3) excluding obviously unrelated articles by reading titles and summaries; (4) retrieving full texts of research reports that may be relevant to our systematic review; (5) deleting studies that did not meet the inclusion criteria; (6) combining articles that reported the same study and removing duplicate articles; (7) making the final decision of study selection.
Two authors (P Xue and LQ Wang) identified studies that met the inclusion criteria independently. Discrepancies were identified and resolved by discussion through a third author (JP Liu).
Data extraction
Data were extracted by one author (WY Li) using a selfdesigned data-extraction table, and verified by another author (LQ Wang). Uncertainties were discussed by the two authors. Extracted information was study methodology, sample size of each group, demographic characteristics of participants, details of intervention and control conditions, and outcomes.
Assessment of methodological quality
Two authors (LQ Wang and WY Li) assessed the methodological quality of RCTs using the Cochrane Collaboration Risk of Bias tool. 11 As recommended by the Cochrane Collaboration, we assessed seven domains: sequence generation, allocation concealment, blinding of participants and personnel to the study protocol, blinding of outcome assessors to the study protocol, incomplete outcome data, selective reporting of outcomes, and other biases (baseline comparability between groups). The risk of bias of included RCTs was categorized as "low", "unclear", or "high" risk of bias in accordance with Cochrane guidelines.
Data analyses
We undertook meta-analysis of the RCTs among which intervention and control conditions were identical or similar using RevMan v5.2 provided by the Cochrane Collaboration. Continuous data were summarized using weighted mean difference (MD) with 95% confidence intervals (CIs) and dichotomous outcomes using relative risk (RR) with 95% CIs. If significant heterogeneity among RCTs was noted, a random-effects model was applied. If significant heterogeneity among RCTs was not observed, a fixedeffects model was used. For data that could not be evaluated, we provided qualitative descriptions. Acupoint injection alone in the intervention group and acupoint injection in combination with other interventions in the intervention group were analyzed separately.
Results
Description of studies
The initial search on December 15, 2013 yielded 310 articles related to acupoint injection for asthma treatment from six databases. After reading titles and abstracts, 251 of these articles were excluded because they were duplicates, nonclinical studies, or had study objectives different from those of our systematic review. By reading full texts, articles that did not meet the inclusion criteria were excluded (Fig. 1) 15, 16, 18, 25 vitamins in one RCT, 17 and Western medicine combined with Chinese herbal medicine in one RCT. 29 Bacillus CalmetteeGuerin polysaccharide nucleic acid (BCG-PSN) was the most used Western medicine in four RCTs, 12, 14, 22, 23 and Chuankezhi injection was the most used Chinese herbal medicine in three RCTs. 15, 16, 18 Four RCTs 13, 14, 17, 21 used only one acupoint [ST-36 (two RCTs), BL13, CV22], whereas the others used multiple acupoints, among which BL13 was used most frequently, followed by EX-B1, ST-36, and CV22. Mean duration of treatment was 32 days (range, 6 h to 3 months) ( 12, 14, 16, 19, 27, 29 reported follow-up duration after completion of treatment ranging from 1 month to 1 year (median duration, 6 months). However, the follow-up information of included RCTs was not available ( Table 2 ).
Risk of bias in included RCTs
Fourteen of the RCTs did not report the methods of randomization, except for four RCTs in which SPSS statistical software 12 and random number tables 15, 18, 25 were applied. Only one RCT 12 provided information about allocation concealment using sealed envelopes. With regard to performance bias, all RCTs were perceived to be high risk because no study used a placebo or other methods to blind participants and personnel to the study protocol. With respect to detection bias, only one RCT 12 which blinded the outcome assessors and statistician was considered to be low risk, and two RCTs which reported that they used binding but did not specify who was blinded had an unclear risk of bias. In terms of attrition bias, three RCTs 12,14,26 were considered to be of high risk. Of these, one RCT reported the prevalence of dropouts before the end of treatment 12 but failed to provide reasons and did not use intention-totreat analyses to handle missing data, and the other two RCTs 14, 26 had missing data but did not mention why. Accessible protocols of any included RCTs were not available, so we had to compare the Methods sections with Results sections for assessment of reporting bias. Three RCTs 18, 19, 25 did not report the results in accordance with what had been described in the Methods section, which was considered to cause a high risk of bias. Other biases were considered to be of low risk on account of comparability of baseline data in 14 RCTs. Overall, the methodological quality of included RCTs was low (Figs. 2 and 3).
Effects of interventions
Three comparisons were applied in the included RCTs: acupoint injections compared with Western medicine (seven RCTs), 13,17,22e24,26,29 acupoint injections plus basic treatment in comparison with basic treatment (eight RCTs), 14e16,18e21,28 and acupoint injection plus basic treatment with Western medicine plus basic treatment (three RCTs). 12, 25, 27 Most of the injected medicine and control therapy varied among RCTs, so data-pooling from these RCTs for meta-analysis was not meaningful except for in four RCTs 16, 18, 22, 23 (Table 3) .
Mortality
One RCT 20 compared acupoint injection (aminophylline and dexamethasone, anisodamine and lidocaine) plus basic treatment with basic treatment. It showed that four patients died in the control group whereas no one died in the treatment group, but a significant difference was not observed.
Symptom improvement rate
A meta-analysis was conducted by pooling data from two RCTs 22, 23 that tested the symptom improvement rate of acupoint injection of BCG-PSN for asthma compared with intramuscular injection of BCG-PSN (RR, 1.55; 95% CI, 1.22e2.22; I 2 Z 0%). Four RCTs 18, 19, 21, 28 compared acupoint injection plus basic treatment with basic treatment, yet only one RCT 19 showed that acupoint injection of aminophylline enhanced the symptom improvement rate significantly (RR, 1.21; 95% CI, 1.02e1.45).
One RCT 27 comparing acupoint injection (triamcinolone acetonide plus nucleotide and casein) plus basic treatment with inhaled (beclomethasone and salbutamol) plus basic treatment and another RCT 12 comparing acupoint injection (BCG-PSN) plus basic treatment with intramuscular injection (BCG-PSN) plus basic treatment did not show significant differences in the symptom improvement rate between groups.
ACT
One RCT
12 in which acupoint injection of BCG-PSN plus basic treatment was compared with intramuscular injection of BCG-PSN plus basic treatment showed a significant difference in improvement of ACT score (MD, 1.02; 95% CI, 0.22e1.82).
Duration of asthma
One RCT 14 comparing acupoint injection of BCG-PSN in combination with basic treatment with basic treatment showed a significant difference in improving the attack time of asthma (MD, À1.45 days; 95% CI, À2.01 to À0.89).
Mean time that asthma was controlled One RCT 13 comparing acupoint injection of triamcinolone acetonide plus lidocaine with the same medicines injected via the intramuscular route showed significant differences for improving the MTAC (MD, À1.50 days; 95% CI, À1.90 to À1.10).
Two RCTs 21, 28 comparing acupoint injection (anisodamine and recombinant human interferon-g, respectively) plus basic treatment with basic treatment showed significant differences for improving the MTAC (MD, À1.50 days and 95% CI, À2.36 to À0.64; MD, À2.48 and 95% CI, À4.03 to À0.93, respectively).
PEF
Three RCTs
13,24,26 compared acupoint injection with Western medicine, two of which 13, 26 showed acupoint injection had a superior effect, whereas the other RCT24 found no significant difference between groups. Acupoint injection (anisodamine and dyphylline and dexamethasone and procaine) compared with intravenous injection (dexamethasone) and acupoint injection (triamcinolone acetonide and lidocaine) compared with intramuscular injection (triamcinolone acetonide and lidocaine) had significant differences with regard to improvement in PEF (MD, 0.79 L/s and 95% CI, 0.59e0.99; MD, 1.12 L/s and 95% CI, 1.02e1.22, respectively).
Three RCTs 15,20,21 compared acupoint injection plus basic treatment with basic treatment, of which one 15 showed that acupoint injection (Chuankezhi) had a significant difference (MD, 0.41 L/s; 95% CI, 0.27e0.55), whereas the other two 20, 21 found no significant differences between groups.
Two RCTs 12,25 compared acupoint injection plus basic treatment with Western medicine plus basic treatment: both RCTs found no significant differences between treatments.
FEV1
Five RCTs 13, 17, 24, 26, 29 (six comparisons) compared acupoint injection with Western medicine, three of which 13, 26, 29 showed that acupoint injection had significant differences whereas the other two found no significant differences. Acupoint injection (anisodamine and dyphylline and dexamethasone and procaine) compared with intravenous injection (dexamethasone), acupoint injection (triamcinolone acetonide and lidocaine) compared with intramuscular injection (triamcinolone acetonide and lidocaine) and acupoint injection (Utilin's and Huangqi injection and Yuxingcao injection) compared with oral (ketotifen plus theophylline sustained-release tablets) and inhaled (beclomethasone plus ventolin) treatment had significant differences for improving FEV1 (MD, 0.50 L and 95% CI, 0.40e0.61; MD, 0.62 L and 95% CI, 0.54e0.70; MD, 0.28 L and 95% CI, 0.09e0.47, respectively).
Four RCTs 15,19e21 compared acupoint injection in combination with basic treatment with basic treatment, Fig. 2 Risk of bias. Authors' judgment about each risk of bias item for each included RCT. three 15, 19, 21 of which showed that acupoint injection had significant differences while the other RCT found no significant differences. Acupoint injection with Chuankezhi, aminophylline or anisodamine showed significant differences for improving FEV1 (MD, 0.36 L and 95% CI 0.12e0.60; MD, 0.58 L and 95% CI, 0.31e0.85; MD, 0.40 L and 95% CI 0.06e0.74, respectively).
FVC
Three RCTs 17, 24, 29 (four comparisons) compared acupoint injection with Western medicine, one of which 29 showed that acupoint injection (utilins and Huangqi injection and Yuxingcao injection) compared with oral medications (ketotifen plus theophylline sustained-release tablets) and inhaled medications (beclomethasone plus ventolin) had significant differences in terms of improving FVC (MD, 0.34 L; 95% CI, 0.09e0.59), whereas the other RCTs found no significant differences.
Two RCTs 15, 19 compared acupoint injection in combination with basic treatment with basic treatment, and both showed that acupoint injection (Chuankezhi and aminophylline) had significant differences in terms of improving FVC (MD, 0.54 L and 95% CI, 0.31e0.77; MD, 0.81 L and 95% CI, 0.60e1.02, respectively).
FEV1/FVC
One RCT 17 (two comparisons) compared acupoint injection with Western medicine: acupoint injection did not improve FEV1/FVC significantly.
FEV1%
Two RCTs
13,26 compared acupoint injection with Western medicine. They showed that acupoint injection (anisodamine and dyphylline and dexamethasone and procaine) compared with intravenous injection (dexamethasone) and acupoint injection (triamcinolone acetonide and lidocaine) compared with intramuscular injection (triamcinolone acetonide and lidocaine) had significant differences in terms of improving FEV1% (MD, 10.50 and 95% CI 6.05e14.95; MD, 11.10 and 95% CI, 9.88e12.32, respectively).
A meta-analysis was conducted by pooling data from two RCTs 16, 18 comparing acupoint injection of Chuankezhi in combination with basic treatment with basic treatment. Significant differences in terms of improvement in FEV1% (MD, 4.76; 95% CI, 2.84e6.68, random-effects model, I 2 Z 77%) were noted.
One RCT 12 compared acupoint injection of BCG-PSN plus basic treatment with intramuscular injection of BCG-PSN plus basic treatment, but did not show acupoint injection improved FEV1% significantly.
VC
One RCT
29 compared acupoint injection (utilins and Huangqi injection and Yuxingcao injection) with oral medications (ketotifen plus theophylline sustained-release tablets) and inhaled medications (beclomethasone plus ventolin), and showed significant differences in terms of improving VC (MD, 0.72 L; 95% CI, 0.52e0.92).
One RCT 19 compared acupoint injection in combination with basic treatment with basic treatment, and showed Fig. 3 Breakdown of each type of risk of bias identified in the included studies. Note: "þ": low risk of bias; "?": unclear risk of bias; "À" high risk of bias. 
Safety
Five RCTs 12, 14, 24, 27, 29 reported adverse events, and showed no significant differences between the acupoint injection group and control group. Adverse events in the acupoint injection group included local skin redness, swelling, and pain, all of which could be relieved rapidly. Serious adverse events were not reported in the included RCTs.
Discussion
This systematic review identified the effectiveness of acupoint injection alone or in combination with basic treatment for asthma patients.
Eleven outcomes were applied to compare the effectiveness of acupoint injection involving three types of comparisons. Results from the included eighteen RCTs were inconsistent. This may have been related to the different medicines and acupoint injections employed in different RCTs. In terms of the symptom improvement rate, only two RCTs showed acupoint injection to be superior to Western medicine in patients with asthma. The diversity of patients and variety of outcome measures may also explain those results. With regard to ACT results, duration of asthma, and the MTAC, acupoint injection used alone or in combination with basic treatment was superior to Western medicine alone or in combination with basic treatment. However, we failed to find RCTs assessing QoL in patients with asthma. In terms of LFTs, the results from the included eighteen RCTs were inconsistent. Acupoint injection may have certain effects on improving ACT results, attack time of asthma, MTAC, and LFTs of patients with asthma. However, considering the relatively poor quality of included RCTs, acupoint injection should be used selectively for asthma treatment. Thirteen out of the eighteen RCTs did not report the outcome of adverse events. Hence, the safety of acupoint injection for asthma remains unclear (though some RCTs showed no significant differences between the acupoint injection group and control group in terms of adverse reactions).
The methodological quality of included RCTs was not high. Most RCTs did not provide sufficient information about generation of randomized sequences or allocation concealment. Hence, selection bias could have been present in RCTs. Performance bias was a high risk because no study used a placebo or other methods to blind participants and personnel to the study protocol. Selection of a control to blind participants and personnel from acupoint injection is difficult, but it is important to blind the outcome assessors and statistician. Also, information regarding detection bias was unclear. Such non-optimal reporting can lead to other biases in assessment. Thus, we highly recommend further RCTs report according to CONSORT and STRICTA statements. 30, 31 Our systematic review had limitations. First, though considerable efforts were made to include all RCTs involving acupoint injection for asthma treatment, we cannot be sure data collection was comprehensive. In addition, owing to the diversity of acupoints and injections, we cannot recommend acupoint injection at specific acupoints or with specific injections that are effective for asthma treatment. Moreover, we cannot provide evidence of acupoint injection for patients with asthma in terms of QoL and long-term effectiveness because of the absence of information on QoL and follow-up data. Finally, our systematic review was limited with regard to generalization of acupoint injection for asthma treatment owing to low methodological quality and poor reporting.
Future RCTs focusing on acupoint injection for asthma treatment should pay more attention to QoL and safety. A follow-up period is necessary to evaluate the long-term effect of acupoint injection for asthma treatment. Also, RCTs with rigorous study designs and high methodological quality should be conducted to avoid potential exaggeration of the therapeutic effects of acupoint injection for asthma treatment. 32 Reporting of RCTs using acupoint injection should be in accordance with CONSORT and STRICTA standards. 30, 31 Further research might compare different acupoints for optimal treatment of asthma.
Conclusions
Based on existing evidence, acupoint injection may be effective for improving ACT results, duration of asthma, MTAC, and LFTs, but the safety of acupoint injection is not clear. The RCTs included in this systematic review had small sample sizes, as well as poor methodological quality and reporting. Thus, rigorously designed, large RCTs are needed to verify the efficacy of acupoint injection for asthma treatment, and to monitor adverse reactions in a standardized manner. In addition, CONSORT and STRICTA guidelines 30, 31 should be followed for objective reporting of results.
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